Table 4. All lead compounds reduce drug resistance significantly.
| Cell line | CAS Nr. | Dosage | Dosage (relative to BVDU) | Cell Count × 103/ml | ||
|---|---|---|---|---|---|---|
| Bortezomib only | Bortezomib plus BVDU | Bortezomib plus Compound | ||||
| RPMI-8226 | 50-53-3 | 0,5 μM | 1/60 | 350 | 160 | 70 |
| RPMI-8226 | 61-00-7 | 0,75 μM | 1/40 | 350 | 160 | 30 |
| RPMI-8226 | 104715-80-2 | 1 μM | 1/30 | 950 | 290 | 240 |
| RPMI-8226 | 161363-17-3 | 1 μM | 1/30 | 950 | 290 | 270 |
| RPMI-8226 | 1222812-38-5 | 1 μM | 1/30 | 510 | 340 | 290 |
| RPMI-8226 | 1222781-87-4 | 1 μM | 1/30 | 510 | 340 | 380 |
| U-937 | 61-00-7 | 0,75 μM | 1/40 | 450 | 250 | 70 |
| U-937 | 104715-80-2 | 0,75 μM | 1/40 | 450 | 250 | 30 |
One lead, acepromazine, performs 5-6 fold better than BVDU (30 μM) at one fortieth of the dosage.